Paul Fishkin, MD
Basic profilePaul Fishkin is an Oncology physician affiliated with Illinois CancerCare. OpenAlex indexes 38 publications with 1,294 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeiGeneProgram year202521 paymentsResearch$77,361
- BeOne MedicinesProgram year20259 paymentsResearch$25,749
- JanssenProgram year20252 paymentsResearch$20,500
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.3%PD-1 inhibitor31.4%Nivolumab59%Pembrolizumab41%Part B, office-administered≥30 patientsNucleoside Metabolic Inhibitor8.6%Azacitidine96%Fluorouracil2%Gemcitabine hydrochloride2%Part B, office-administered≥17 patients+ 14 more classes in this area
Blood & clotting
31.4%Iron, parenteral preparations19.4%Ferric carboxymaltose99%Iron dextran1%Part B, office-administered≥28 patientsErythropoiesis-stimulating Agent7.5%Darbepoetin alfa91%Epoetin alfa9%Part B, office-administered≥18 patients+ 3 more classes in this area
Metabolism & gastrointestinal
9.6%Substance P/Neurokinin-1 Receptor Antagonist5%Aprepitant100%Part B, office-administered≥27 patientsOther antiemetics2.2%Fosaprepitant100%Part B, office-administered≥11 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Veeder, MD
Illinois CancerCare
Gary Macvicar, MD
Illinois CancerCare
Nguyet Le-Lindqwister, MD
Illinois CancerCare
Francois Geoffroy, MD
Illinois CancerCare
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”